Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Assets (2022 - 2025)

Corvus Pharmaceuticals has reported Assets over the past 4 years, most recently at $80.5 million for Q3 2025.

  • Quarterly results put Assets at $80.5 million for Q3 2025, up 36.83% from a year ago — trailing twelve months through Sep 2025 was $80.5 million (up 36.83% YoY), and the annual figure for FY2024 was $68.9 million, up 51.27%.
  • Assets for Q3 2025 was $80.5 million at Corvus Pharmaceuticals, down from $89.5 million in the prior quarter.
  • Over the last five years, Assets for CRVS hit a ceiling of $101.3 million in Q1 2022 and a floor of $40.1 million in Q1 2024.
  • Median Assets over the past 4 years was $64.6 million (2024), compared with a mean of $67.9 million.
  • Biggest five-year swings in Assets: crashed 42.54% in 2023 and later surged 51.27% in 2024.
  • Corvus Pharmaceuticals' Assets stood at $68.2 million in 2022, then crashed by 33.25% to $45.6 million in 2023, then soared by 51.27% to $68.9 million in 2024, then increased by 16.79% to $80.5 million in 2025.
  • The last three reported values for Assets were $80.5 million (Q3 2025), $89.5 million (Q2 2025), and $59.4 million (Q1 2025) per Business Quant data.